Scott Durbin Joins Aastrom as CFO
Aastrom Biosciences, a developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, has hired Scott Durbin as chief financial officer (CFO). Durbin brings more than 15 years of healthcare-related banking, financial and corporate development experience to Aastrom.
Durbin was formerly chief operating officer (COO) and CFO of Prescient Medical, which develops diagnostic and therapeutic catheter-based medical devices for the treatment of severe coronary artery disease. While at Prescient, Durbin raised more than US$60m in private equity financing and helped advance the company through early-stage research, development and regulatory approval. Previously, he served as a finance and corporate development consultant for Scios, a Johnson & Johnson subsidiary, and Alteon. Prior to this consulting work, he was an investment banker with Lehman Brothers, where he completed more than US$5bn in financings and merger and acquisition (M&A) transactions for life science companies.
Durbin earned an MPH in health management from the Yale University School of Medicine & School of Management and a BS from the University of Michigan.